ClinicalTrials.gg
RecruitingNCT07741721Updated Oct 23, 2026

Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)

An interventional study of In-hospital staged complete revascularization and Out-of-hospital staged complete revascularization in Myocardial Infarction (MI), sponsored by Chonnam National University Hospital. Recruiting at 30 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 23, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,252
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.

Planned enrollment
3rd of 11
1,252 · median 860
Started
2026
with 2 others
No phase
9 of 12
6 open now
Registered
11th of 12
by date

Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 11th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Myocardial Infarction by Chonnam National University Hospital, or all of them as a file.
02

Study summary

This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be randomized in a 1:1 ratio to either in-hospital staged complete revascularization with PCI of non-IRA lesions performed on a separate day during hospitalization, at least 48 hours after PCI of the IRA, or out-of-hospital staged complete revascularization with PCI of non-IRA lesions performed after discharge between 15 and 45 days of randomization. In both groups, non-IRA lesions with 50-69% stenosis will be evaluated using FFR.

Read the detailed description
  • Study Objectives: To determine the optimal timing of staged complete revascularization guided by fractional flow reserve (FFR) (in-hospital staged complete revascularization vs. out-of-hospital staged complete revascularization) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
  • Study Background: Approximately half of patients with STEMI have multivessel coronary artery disease, which is associated with worse clinical outcomes than single vessel disease. Complete revascularization has become the standard interventional strategy for the management of these patients. Regarding the timing of complete revascularization, two recent randomized clinical trials demonstrated that immediate complete revascularization was non-inferior to staged complete revascularization in patients with STEMI. In this context, the 2023 European guidelines give a class IA recommendation for complete revascularization, either during the index procedure or within 45 days. The 2025 American guidelines recommend immediate complete revascularization with a class IIb recommendation for hemodynamically stable patients with STEMI and low-complex anatomy. However, in these trials, planned staged revascularization in the staged group was performed after hospital discharge rather than during the index admission. In those previous trials, the timing of staged revascularization was median 15 days (IQR 4-28) in the BIOVASC trial and median 37 days (IQR 30-43) in the MULTISTARS AMI trial, and most clinical events in the staged group (mainly due to unplanned revascularization and myocardial infarction) had occurred during the early phase after the index procedure with the possibility of progression of a non-infarct related artery (non-IRA) lesion before the staged procedure. Greater inflammatory status during the acute phase of myocardial infarction might be associated with these findings. The OPTION-STEMI trial, which compared immediate and staged complete revascularization during index hospitalization, failed to demonstrate non-inferiority for the primary endpoint at 1 year (13% in the immediate complete revascularization group and 11% in the staged complete revascularization group; hazard ratio 1.24; 95% confidence interval 0.86-1.79; P for non-inferiority = 0.024). Therefore, it remains unclear whether the treatment effect differs between in-hospital and out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. The investigators designed a prospective, open-label, multicenter, superiority trial to evaluate the efficacy and safety of in-hospital staged complete revascularization compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. Non-IRA lesions with 50-69% stenosis will be assessed using FFR, whereas those with ≥ 70% stenosis will undergo revascularization without FFR assessment. The investigators hypothesize that in-hospital staged complete revascularization may mitigate the risk of early progression of non-IRA lesions, compared with out-of-hospital staged complete revascularization, without increasing the procedural risk associated with immediate complete revascularization.
  • Study Hypothesis: In-hospital staged complete revascularization would reduce the risk of the primary composite endpoint (a composite of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization) at 12 months compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease.
03

Conditions studied

  • Myocardial Infarction (MI)

Keywords

  • ST-segment myocardial infarction
  • Multivessel coronary artery disease
  • Complete revascularization
  • Timing
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥19 years
  • ST-segment elevation myocardial infarction (STEMI): ST-segment elevation ≥ 0.1 mV in at least two contiguous leads, or New-onset left bundle branch block (LBBB)
  • Primary PCI within 12 h after symptom development
  • At least 1 non-infarct related artery (non-IRA) with diameter ≥ 2.5 mm and 50% stenosis by visual estimation

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock at initial presentation or after infarct-related artery (IRA) treatment
  • Thrombolysis in myocardial infarction flow at non-IRA ≤ 2
  • Severe procedural complications during primary percutaneous coronary intervention that, in the judgement of the operator, preclude study enrollment
  • Non-IRA lesion unsuitable for percutaneous coronary intervention (PCI) treatment that, in the judgement of the operator, preclude study enrollment
  • Chronic total occlusion in a non-IRA
  • History of anaphylaxis to contrast agent
  • Pregnancy and lactation
  • \< 1 year
  • Severe valvular heart disease
  • History of coronary artery bypass grafting (CABG) or planned CABG
  • Fibrinolysis therapy prior to admission
  • Severe asthma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,252 participants (estimated)

Study arms

  • Experimental
    In-hospital staged complete revascularization

    In the in-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

    Procedure: In-hospital staged complete revascularization

  • Active comparator
    Out-of-hospital staged complete revascularization

    In the out-of-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

    Procedure: Out-of-hospital staged complete revascularization

Interventions

  • ProcedureIn-hospital staged complete revascularization

    PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

  • ProcedureOut-of-hospital staged complete revascularization

    PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization

    Composite of all-cause death, nonfatal myocardial infarction, or all unplanned

    Time frame: At 12 months after randomization

Secondary outcomes

  1. Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization

    Composite of all-cause death, nonfatal myocardial infarction, or all unplanned

    Time frame: At 1, 6, 24, 36, 48, and 60 months after randomization

  2. All-cause death

    All-cause death

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  3. Nonfatal myocardial infarction

    Nonfatal myocardial infarction

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  4. All unplanned revascularization

    All unplanned revascularization

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  5. Cardiac death

    Cardiac death

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  6. Non-cardiac death

    Non-cardiac death

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  7. Nonfatal spontaneous myocardial infarction

    Nonfatal spontaneous myocardial infarction

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  8. Nonfatal procedure-related myocardial infarction

    Nonfatal procedure-related myocardial infarction

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  9. Target-lesion revascularization

    Target-lesion revascularization

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  10. Target-vessel revascularization

    Target-vessel revascularization

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  11. Non-target vessel revascularization

    Non-target vessel revascularization

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  12. Hospitalization for unstable angina

    Hospitalization for unstable angina

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  13. Hospitalization for heart failure

    Hospitalization for heart failure

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  14. Stent thrombosis

    Stent thrombosis

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  15. Stroke

    Stroke

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  16. Major bleeding

    Major bleeding

    Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization

  17. Contrast-induced nephropathy

    Contrast-induced nephropathy

    Time frame: At hospital discharge (up to 30 days)

07

Study locations

1 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2031, 59 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 59 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2026
First posted
Aug 3, 2026
StartActual
Aug 21, 2026was Sep 2026
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2035
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
30 sites changed recruiting status (29 now not yet recruiting, 1 now recruiting)
Show 30 sites
  • Bucheon Sejong Hospital · Bucheon-si, South Koreano status→Not yet recruiting
  • Gyeongsang National University Changwon Hospital · Changwon, South Koreano status→Not yet recruiting
  • Samsung Changwon Medical Center · Changwon, South Koreano status→Not yet recruiting
  • Soon Chun Hyang University Hospital Cheonan · Cheonan, South Koreano status→Not yet recruiting
  • Chungbuk National University Hospital · Cheongju-si, South Koreano status→Not yet recruiting
  • Kangwon National University Hospital · Chuncheon, South Koreano status→Not yet recruiting
  • Daegu Catholic University Medical Center · Daegu, South Koreano status→Not yet recruiting
  • Keimyung University Dongsan Hospital · Daegu, South Koreano status→Not yet recruiting
  • Kyungpook National University Hospital · Daegu, South Koreano status→Not yet recruiting
  • Yeongnam University Medical Center · Daegu, South Koreano status→Not yet recruiting
  • Chungnam National University Hospital · Daejeon, South Koreano status→Not yet recruiting
  • Chonnam National University Hospital · Gwangju, South Koreano status→Recruiting
  • Chosun University Hospital · Gwangju, South Koreano status→Not yet recruiting
  • Gwangju Veterans Hospital · Gwangju, South Koreano status→Not yet recruiting
  • Kwangju Christian Hospital · Gwangju, South Koreano status→Not yet recruiting
  • Chung-Ang University Gwangmyeong Hospital · Gwangmyeong, South Koreano status→Not yet recruiting
  • Jeju National University Hospital · Jeju City, South Koreano status→Not yet recruiting
  • Jeonbuk National University Hospital · Jeonju, South Koreano status→Not yet recruiting
  • Presbyterian Medical Center · Jeonju, South Koreano status→Not yet recruiting
  • Gyeongsang National University Hospital · Jinju, South Koreano status→Not yet recruiting
  • Inje University Busan Paik Hospital · Pusan, South Koreano status→Not yet recruiting
  • Inje University Haeundae Paik Hospital · Pusan, South Koreano status→Not yet recruiting
  • Kosin University Gospel Hospital · Pusan, South Koreano status→Not yet recruiting
  • Pusan National University Hospital · Pusan, South Koreano status→Not yet recruiting
  • Koera University Guro Hospital · Seoul, South Koreano status→Not yet recruiting
  • Korea University Anam Hospital · Seoul, South Koreano status→Not yet recruiting
  • Yonsei University Health System, Gangnam Severance Hospital · Seoul, South Koreano status→Not yet recruiting
  • St. Carollo General Hospital · Suncheon, South Koreano status→Not yet recruiting
  • Ajou University Hospital · Suwon, South Koreano status→Not yet recruiting
  • Pusan National University Yangsan Hospital · Yangsan, South Koreano status→Not yet recruiting
Oct 23, 2026
Start date
Sep 1, 2026→Aug 21, 2026 (actual)
Oct 23, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionComposite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization: how it is measured was reworded
Oct 23, 2026
Secondary outcomes
17 description edited
What changed in the outcomes
  • DescriptionAll unplanned revascularization: how it is measured was reworded
  • DescriptionAll-cause death: how it is measured was reworded
  • DescriptionCardiac death: how it is measured was reworded
  • DescriptionComposite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization: how it is measured was reworded
  • DescriptionContrast-induced nephropathy: how it is measured was reworded
  • DescriptionHospitalization for heart failure: how it is measured was reworded
  • DescriptionHospitalization for unstable angina: how it is measured was reworded
  • DescriptionMajor bleeding: how it is measured was reworded
  • DescriptionNon-cardiac death: how it is measured was reworded
  • DescriptionNon-target vessel revascularization: how it is measured was reworded
  • DescriptionNonfatal myocardial infarction: how it is measured was reworded
  • DescriptionNonfatal procedure-related myocardial infarction: how it is measured was reworded
  • DescriptionNonfatal spontaneous myocardial infarction: how it is measured was reworded
  • DescriptionStent thrombosis: how it is measured was reworded
  • DescriptionStroke: how it is measured was reworded
  • DescriptionTarget-lesion revascularization: how it is measured was reworded
  • DescriptionTarget-vessel revascularization: how it is measured was reworded
Oct 23, 2026
Title
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    30 sites changed recruiting status (29 now not yet recruiting, 1 now recruiting)
    Show 30 sites
    • Bucheon Sejong Hospital · Bucheon-si, South Koreano status→Not yet recruiting
    • Gyeongsang National University Changwon Hospital · Changwon, South Koreano status→Not yet recruiting
    • Samsung Changwon Medical Center · Changwon, South Koreano status→Not yet recruiting
    • Soon Chun Hyang University Hospital Cheonan · Cheonan, South Koreano status→Not yet recruiting
    • Chungbuk National University Hospital · Cheongju-si, South Koreano status→Not yet recruiting
    • Kangwon National University Hospital · Chuncheon, South Koreano status→Not yet recruiting
    • Daegu Catholic University Medical Center · Daegu, South Koreano status→Not yet recruiting
    • Keimyung University Dongsan Hospital · Daegu, South Koreano status→Not yet recruiting
    • Kyungpook National University Hospital · Daegu, South Koreano status→Not yet recruiting
    • Yeongnam University Medical Center · Daegu, South Koreano status→Not yet recruiting
    • Chungnam National University Hospital · Daejeon, South Koreano status→Not yet recruiting
    • Chonnam National University Hospital · Gwangju, South Koreano status→Recruiting
    • Chosun University Hospital · Gwangju, South Koreano status→Not yet recruiting
    • Gwangju Veterans Hospital · Gwangju, South Koreano status→Not yet recruiting
    • Kwangju Christian Hospital · Gwangju, South Koreano status→Not yet recruiting
    • Chung-Ang University Gwangmyeong Hospital · Gwangmyeong, South Koreano status→Not yet recruiting
    • Jeju National University Hospital · Jeju City, South Koreano status→Not yet recruiting
    • Jeonbuk National University Hospital · Jeonju, South Koreano status→Not yet recruiting
    • Presbyterian Medical Center · Jeonju, South Koreano status→Not yet recruiting
    • Gyeongsang National University Hospital · Jinju, South Koreano status→Not yet recruiting
    • Inje University Busan Paik Hospital · Pusan, South Koreano status→Not yet recruiting
    • Inje University Haeundae Paik Hospital · Pusan, South Koreano status→Not yet recruiting
    • Kosin University Gospel Hospital · Pusan, South Koreano status→Not yet recruiting
    • Pusan National University Hospital · Pusan, South Koreano status→Not yet recruiting
    • Koera University Guro Hospital · Seoul, South Koreano status→Not yet recruiting
    • Korea University Anam Hospital · Seoul, South Koreano status→Not yet recruiting
    • Yonsei University Health System, Gangnam Severance Hospital · Seoul, South Koreano status→Not yet recruiting
    • St. Carollo General Hospital · Suncheon, South Koreano status→Not yet recruiting
    • Ajou University Hospital · Suwon, South Koreano status→Not yet recruiting
    • Pusan National University Yangsan Hospital · Yangsan, South Koreano status→Not yet recruiting
    Start date Sep 1, 2026→Aug 21, 2026 (now actual)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionComposite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization: how it is measured was reworded
    Secondary outcomes 17 description edited
    What changed in the outcomes
    • DescriptionAll unplanned revascularization: how it is measured was reworded
    • DescriptionAll-cause death: how it is measured was reworded
    • DescriptionCardiac death: how it is measured was reworded
    • DescriptionComposite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization: how it is measured was reworded
    • DescriptionContrast-induced nephropathy: how it is measured was reworded
    • DescriptionHospitalization for heart failure: how it is measured was reworded
    • DescriptionHospitalization for unstable angina: how it is measured was reworded
    • DescriptionMajor bleeding: how it is measured was reworded
    • DescriptionNon-cardiac death: how it is measured was reworded
    • DescriptionNon-target vessel revascularization: how it is measured was reworded
    • DescriptionNonfatal myocardial infarction: how it is measured was reworded
    • DescriptionNonfatal procedure-related myocardial infarction: how it is measured was reworded
    • DescriptionNonfatal spontaneous myocardial infarction: how it is measured was reworded
    • DescriptionStent thrombosis: how it is measured was reworded
    • DescriptionStroke: how it is measured was reworded
    • DescriptionTarget-lesion revascularization: how it is measured was reworded
    • DescriptionTarget-vessel revascularization: how it is measured was reworded
    Title Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741721
Lead sponsor
Chonnam National University Hospital
Responsible party
Min Chul Kim, MD (Professor, Chonnam National University Hospital) — Principal investigator
First posted
Aug 3, 2026
Start date
Aug 21, 2026
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2035 (estimated)
Last update
Oct 23, 2026

Study contacts

Min Chul Kim, MD, PhD
Contact
kmc3242@hanmail.net
82-10-4606-2643
Youngkeun Ahn, MD, PhD
principal investigator · Chonnam National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion